Table 5a: Characteristics of Non-Randomized Studies Excluded From the Review.
Study | Enrolment period | Design | Sample size | Type of lesion | Intervention Strategy | Follow-up-Months | Primary End Point | Secondary End points |
---|---|---|---|---|---|---|---|---|
Albiero et al | 1993–95 | Multicenter Case series (Retrospective) | IVUS 158 Angio 154 | De novo, native | Stenting in all patients | 6 | 6-month angiographic restenosis rate | MACE, repeat PTCA & CABG |
Blasini et al | 1994-95 | Single centre case series (Retrospective) | IVUS 105 Angio 107 | De novo, native, SVG, restenotic | Stenting in all patients | 6 | 6-month angiographic restenosis rate, MLD, % diameter stenosis | |
Choi | 1997 | Single centre case series (Retrospective) | IVUS 178 Angio 100 | De novo, native | Stenting in all patients | 6 | Resource utilization | Death, MI, re PTCA, CABG, TVR, MACE |
CRUISE Fitzgerald 2000 | April 1996–May 1997 | Prospective multicenter, observational; substudy of a RCT | IVUS 270 Angio 229 | De novo & restenotic, native coronary, up to 2 stents | Stenting in all patients | 9 | Angiographic MSD & IVUS MSD & MSA @ 6 months | MACE (death, MI, TVR) @ 9 months |
PRESTO Orford 2004 | ? | Prospective multicenter, observational; substudy of a RCT | IVUS 796 Angio 8,274 | De novo &r restenotic, native coronary artery or vein graft lesions | Stenting in all patients | 9 | Incidence of death, MI or ischemia driven TVR @ 9 months | - |
Angio angiography; IVUS intravascular ultrasound; MACE major adverse cardiac events; Ml myocardial infarction; PTCA percutaneous coronary interventions; CABG coronary artery bypass; TVR target vessel revascularization; MSD minimal stent diameter